Previous 10 | Next 10 |
IVERIC bio, Inc. (ISEE) Q3 2020 Earnings Conference Call November 02, 2020 8:00 AM ET Company Participants Kathy Galante - Investor Relations Glenn Sblendorio - Chief Executive Officer & President Dave Carroll - Chief Financial Officer Pravin Dugel - Chief Strategy & Business Officer ...
IVERIC bio (ISEE): Q3 GAAP EPS of -$0.27 misses by $0.05.Cash, cash equivalents and available for sale securities of $231.1MPress Release For further details see: IVERIC bio EPS misses by $0.05
- Conference Call and Webcast Today, November 2, 2020, at 8:00 a.m. ET - IVERIC bio, Inc. (Nasdaq: ISEE) today announced financial and operating results for the fiscal quarter ended September 30, 2020 and provided a general business update. “It has been a landmark...
IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the Company will participate in the following, upcoming, virtual investor conferences in November: 29 th Annual Credit Suisse Virtual Healthcare Conference Glenn P. Sblendorio, Chief Executive Officer and President...
IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its third quarter 2020 financial and operating results on Monday, November 2, 2020. Following the announcement, the IVERIC bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Time t...
IVERIC bio, Inc. (Nasdaq: ISEE) today reported that on October 1, 2020, the Company granted a newly hired employee a non-statutory option to purchase 14,000 shares of the Company’s common stock. This grant was made pursuant to the Company’s 2019 Inducement Stock Incent...
IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the Company will participate in the following upcoming virtual investor conferences in September: Citi 15 th Annual BioPharma Virtual Conference 2020 on Wednesday, September 9 and Thursday, September 10, 2020, IVERIC bio will hos...
IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the positive Phase 3 results from its GATHER1 clinical trial with Zimura ® (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy (GA) secondary to age-related macular degenerat...
FAT Brands (NASDAQ: FAT ) +170% on the acquisition of the Johnny Rockets restaurant chain. More news on: FAT Brands Inc., NTN Buzztime, Inc., Regional Health Properties, Inc., Stocks on the move, , Read more ...
The following slide deck was published by IVERIC bio, Inc. in conjunction with their 2020 Q2 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
Astellas Completes Acquisition of Iveric Bio PR Newswire TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced that it has successfully completed the acquisit...
Shares of IVERIC bio, Inc. (NASDAQ: ISEE) traded at a new 52-week high today and are currently trading at $39.73. So far today, approximately 1.78M shares have been exchanged, as compared to an average 30-day volume of 5.04M shares. IVERIC bio, Inc., a biopharmaceutical company, discovers and...
IVERIC bio, Inc. (NASDAQ: ISEE) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 1.93% on the day to $38.77. IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal disease...